Avoid common mistakes on your manuscript.
Recent retrospective evidence has underlined the possibility of preventing psoriatic arthritis (PsA) onset in patients suffering from psoriasis (PsO) by using systemic treatments , particularly biologics [1, 2]. However, there are some conflicting data stating the opposite, with a greater risk of PsA among biologics users [3]. Importantly, none of these analyses highlighted any difference in terms of arthritis prevention in PsO among the various systemic therapies, apart from the study by Singla et al. [4]. In detail, these authors retrospectively evaluated the electronic health record database of PsO patients to assess the risk of incident inflammatory arthritis after initiation of biological therapies over a mean time span of 2.4 years, finding the risk of developing inflammatory arthritis to be significantly lower in patients under treatment with IL12/23 inhibitors (adjusted HR 0.58, 95% CI 0.43–0.76) or IL-23 inhibitors (0.41, 0.17–0.95) compared to patients treated with TNF inhibitors, while no significant difference was observed between IL-17 inhibitors (0.86, 0.54–1.38) and TNF inhibitors. However, it is well known that such retrospective observational epidemiological studies on drug effects may be influenced by two main limitations, protopathic bias (i.e., dermatologists were treating presumed psoriatic arthritis—PsA) and confounding by indication (i.e., dermatologists tended to use more TNF inhibitors in suspected PsA compared to IL-12/23 inhibitors) [5]. Besides, there are other possible patient-related variables that have not been considered by such studies possibly affecting their findings; thus, only a stratification according to these factors would ensure a reliable evaluation of biologics efficacy in reducing the likelihood of developing arthritis. In this regard, it is of utmost importance to underline that patient-related risk factors may impact in a different way in terms of timing of PsA development. Indeed, based on the recently released EULAR (European League Against Rheumatism) points to consider on PsO to PsA transition, it is possible to identify a phase of “psoriasis at higher risk for PsA” that is typified by medium- to long-term risk factors (average of 7–12 years before PsA onset), including severe skin involvement, nail psoriasis, obesity and familial history for PsA, and a phase of “subclinical PsA” encompassing short-term risk factors (average of 1–3 years before PsA onset), including arthralgia and imaging evidence of synovio-entheseal inflammation (Fig. 1) [6, 7]. Based on the above, we strongly believe that only prospective studies designed according to a precise stratification of the above-mentioned risk factors and considering their temporal impact on PsA development [8] may clarify whether biologics prevent the transition toward a clinical PsA. In this regard, we recently published a case series focusing on the “subclinical PsA” stage, showing the possibility to “reverse” such a phase (with improvement/remission of arthralgia and/or synovio-entheseal inflammation on imaging) using guselkumab [9]. However, prospective controlled trials on large samples are needed to confirm these preliminary data.
Transition from psoriasis to clinical psoriatic arthritis (PsA) goes through two stages: (1) “psoriasis at higher risk for PsA,” including patients with a medium-/long-term risk (average of 7–12 years) of developing PsA (i.e., those with severe skin involvement, nail psoriasis, obesity, and/or familial history for PsA); (2) “subclinical PsA,” including patients with a short-term risk (average of 1–3 years) of developing PsA (i.e., those with arthralgia and/or imaging evidence of synovio-entheseal inflammation). Such phases precede “clinical PsA,” which may present with three main patterns, including “peripheral,” “oligoarthritis,” and “articular erosions”
Data Availability
Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.
References
Gisondi P, Bellinato F, Targher G, Idolazzi L, Girolomoni G. Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis. Ann Rheum Dis. 2021;81:68 (annrheumdis-2021-219961).
Acosta Felquer ML, LoGiudice L, Galimberti ML, Rosa J, Mazzuoccolo L, Soriano ER. Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis. Ann Rheum Dis. 2022;81(1):74–9.
Meer E, Merola JF, Fitzsimmons R, Love TJ, Wang S, Shin D, et al. Does biologic therapy impact the development of PsA among patients with psoriasis? Ann Rheum Dis. 2022;81(1):80–6.
Singla S, Putman M, Liew J, Gordon K. Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study. Lancet Rheumatol. 2023;5(4):e200–7.
Ogdie A, Scher JU. Prevention of psoriatic arthritis: the next frontier. Lancet Rheumatol. 2023;5(4):e170–1.
Zabotti A, De Marco G, Gossec L, Baraliakos X, Aletaha D, Iagnocco A, et al. EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis. Ann Rheum Dis 2023;82(9):1162–70.
De Marco G, Zabotti A, Baraliakos X, Iagnocco A, Aletaha D, Gisondi P, et al. Characterisation of prodromal and very early psoriatic arthritis: a systematic literature review informing a EULAR taskforce. RMD Open. 2023;9(2): e003143.
Zabotti A, De Lucia O, Sakellariou G, Batticciotto A, Cincinelli G, Giovannini I, et al. Predictors, Risk Factors, and Incidence Rates of Psoriatic Arthritis Development in Psoriasis Patients: A Systematic Literature Review and Meta-Analysis. Rheumatol Ther. 2021. https://doi.org/10.1007/s40744-021-00378-w.
Zabotti A, Giovannini I, McGonagle D, De Vita S, Stinco G, Errichetti E. Arthritis Interception in Patients with Psoriasis Treated with Guselkumab. Dermatol Ther. 2022;12(1):5–8.
Acknowledgements
Authorship
All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.
Funding
No funding or sponsorship was received for this study or publication of this article.
Author information
Authors and Affiliations
Contributions
Enzo Errichetti and Alen Zabotti: concept, design, and writing of the manuscript. The authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Disclosures
Enzo Errichetti and Alen Zabotti have nothing to disclose for this manuscript.
Compliance with Ethics Guidelines
This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by the authors.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Errichetti, E., Zabotti, A. Biologics in Prevention of Psoriasis to Psoriatic Arthritis Transition: The Need of Prospective Analyses and Stratification According to Time-Related Risk Factors. Dermatol Ther (Heidelb) 14, 1–3 (2024). https://doi.org/10.1007/s13555-023-01072-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13555-023-01072-1